IM21 CART / Beijing Imunopharm - LARVOL DELTA

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma (clinicaltrials.gov) - P1; N=15; Recruiting; Sponsor: Peking Union Medical College Hospital; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=10; Recruiting; Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

Clinical • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology